These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21748440)

  • 21. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy.
    Culig Z; Klocker H; Bartsch G; Hobisch A
    Am J Pharmacogenomics; 2001; 1(4):241-9. PubMed ID: 12083956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
    Warriar N; Pagé N; Koutsilieris M; Govindan MV
    Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.
    Yeh S; Chang C
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5517-21. PubMed ID: 8643607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
    Miyamoto H; Yeh S; Wilding G; Chang C
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7379-84. PubMed ID: 9636157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
    Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
    Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
    Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxyflutamide may not always be a pure antiandrogen.
    Yeh S; Miyamoto H; Chang C
    Lancet; 1997 Mar; 349(9055):852-3. PubMed ID: 9121269
    [No Abstract]   [Full Text] [Related]  

  • 29. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
    Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
    Berrevoets CA; Umar A; Trapman J; Brinkmann AO
    Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line.
    Chang HC; Chen SC; Chen J; Hsieh JT
    J Formos Med Assoc; 2005 Sep; 104(9):652-8. PubMed ID: 16276440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145.
    Sigala S; Tognazzi N; Rizzetti MC; Faraoni I; Missale C; Bonmassar E; Spano P
    Eur J Endocrinol; 2002 Sep; 147(3):407-15. PubMed ID: 12213679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
    Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
    Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
    Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
    Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity.
    Ting HJ; Bao BY; Hsu CL; Lee YF
    Endocrine; 2005 Feb; 26(1):1-9. PubMed ID: 15805579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
    Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
    Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
    Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
    Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of RFG/ELE1alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids.
    Tekur S; Lau KM; Long J; Burnstein K; Ho SM
    Mol Carcinog; 2001 Jan; 30(1):1-13. PubMed ID: 11255259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.